Washington University Purchases 70,121 Shares of Maze Therapeutics, Inc. $MAZE

Washington University raised its holdings in shares of Maze Therapeutics, Inc. (NASDAQ:MAZE) by 33.3% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 280,802 shares of the company’s stock after acquiring an additional 70,121 shares during the quarter. Maze Therapeutics makes up 5.9% of Washington University’s investment portfolio, making the stock its 2nd biggest holding. Washington University owned about 0.58% of Maze Therapeutics worth $11,634,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Ameritas Investment Partners Inc. increased its stake in Maze Therapeutics by 82.6% in the third quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock valued at $42,000 after purchasing an additional 738 shares during the last quarter. Russell Investments Group Ltd. grew its position in shares of Maze Therapeutics by 947.8% in the 3rd quarter. Russell Investments Group Ltd. now owns 1,907 shares of the company’s stock valued at $49,000 after buying an additional 1,725 shares during the last quarter. China Universal Asset Management Co. Ltd. acquired a new stake in Maze Therapeutics during the 3rd quarter worth $52,000. Legal & General Group Plc lifted its position in Maze Therapeutics by 387.0% in the second quarter. Legal & General Group Plc now owns 4,242 shares of the company’s stock valued at $52,000 after acquiring an additional 3,371 shares during the last quarter. Finally, Tower Research Capital LLC TRC boosted its stake in Maze Therapeutics by 452.5% in the second quarter. Tower Research Capital LLC TRC now owns 4,608 shares of the company’s stock valued at $57,000 after acquiring an additional 3,774 shares in the last quarter.

Insider Buying and Selling

In other Maze Therapeutics news, SVP Amy Bachrodt sold 5,000 shares of the firm’s stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $46.04, for a total value of $230,200.00. Following the sale, the senior vice president directly owned 12,965 shares of the company’s stock, valued at approximately $596,908.60. This trade represents a 27.83% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CMO Harold Bernstein sold 30,000 shares of Maze Therapeutics stock in a transaction dated Tuesday, March 10th. The shares were sold at an average price of $50.45, for a total value of $1,513,500.00. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 112,500 shares of company stock worth $5,132,812.

Maze Therapeutics Trading Down 2.7%

Shares of NASDAQ MAZE opened at $29.05 on Thursday. Maze Therapeutics, Inc. has a 52 week low of $6.71 and a 52 week high of $53.65. The stock has a market cap of $1.44 billion, a price-to-earnings ratio of -8.99 and a beta of 5.14. The company’s 50-day moving average price is $44.79 and its 200 day moving average price is $37.94.

Maze Therapeutics (NASDAQ:MAZE) last released its earnings results on Wednesday, March 25th. The company reported ($0.65) EPS for the quarter, topping the consensus estimate of ($0.73) by $0.08.

Analysts Set New Price Targets

Several analysts have recently weighed in on the company. BTIG Research reissued a “buy” rating and issued a $46.00 target price on shares of Maze Therapeutics in a report on Wednesday, March 25th. Guggenheim raised their target price on shares of Maze Therapeutics from $46.00 to $58.00 and gave the stock a “buy” rating in a research report on Wednesday, March 4th. Wall Street Zen upgraded shares of Maze Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, March 28th. Weiss Ratings reissued a “sell (d)” rating on shares of Maze Therapeutics in a research report on Thursday, January 22nd. Finally, JPMorgan Chase & Co. increased their target price on shares of Maze Therapeutics from $52.00 to $58.00 and gave the stock an “overweight” rating in a research note on Tuesday. Three equities research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $66.44.

Maze Therapeutics Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.